Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Haemopoietic Growth Factor

Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF

Bone Marrow Transplantation volume 32, pages 31–34 (2003)Cite this article

Summary:

Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is frequently used to mobilize CD34+ cells in healthy donors and patient with malignant diseases prior to peripheral blood stem cell (PBSC) harvest. To analyze the effects of rhG-CSF on morphology and genotype of white blood cells, a novel multiparametric cell scanning system that combines morphologic, immune and genotypic analyses of the same cells was used. We report here that tetraploid myeloid cells are present in the peripheral blood of donors treated with rhG-CSF. The tetraploidy was detected in up to 0.6% of differentiated myeloid cells and all observed CD34+ cells were diploid. Thus, short treatment with rhG-CSF of PBSC donors induces numerfical chromosomal alterations in a small subset of mature myeloid cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Welte K, Gabrilove J, Bronchud MH et al. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996; 88: 1907–1929.

    CAS  Google Scholar 

  2. Link DC . Mechanisms of granulocyte colony-stimulating factor-induced hematopoietic progenitor-cell mobilization. Semin Hematol 2000; 37: 25–32.

    Article  CAS  Google Scholar 

  3. Cleaver SA, Goldman JM . Use of G-CSF to mobilise PBSC in normal healthy donors–an international survey. Bone Marrow Transplant 1998; 21 (Suppl. 3): S29–S31.

    Google Scholar 

  4. Price TH . The use of G-CSF in normal neutrophil donors. Ann Med Interne (Paris) 2000; 151: 115–122.

    CAS  Google Scholar 

  5. Volk EE, Domen RE, Smith ML . An examination of ethical issues raised in the pretreatment of normal volunteer granulocyte donors with granulocyte colony-stimulating factor. Arch Pathol Lab Med 1999; 123: 508–513.

    CAS  PubMed  Google Scholar 

  6. Anderlini P, Donato M, Chan KW et al. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion 1999; 39: 555–560.

    Article  CAS  Google Scholar 

  7. Anderlini P, Korbling M, Dale D et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997; 90: 903–908.

    CAS  Google Scholar 

  8. Tidow N, Kasper B, Welte K . Clinical implications of G-CSF receptor mutations. Crit Rev Oncol Hematol 1998; 28: 1–6.

    Article  CAS  Google Scholar 

  9. Stroncek D, Anderlini P . Mobilized PBPC concentrates: a maturing blood component. Transfusion 2001; 41: 168–171.

    Article  CAS  Google Scholar 

  10. Stroncek DF, Yau YY, Oblitas J, Leitman SF . Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone. Transfusion 2001; 41: 1037–1044.

    Article  CAS  Google Scholar 

  11. Platzbecker U, Prange-Krex G, Bornhauser M et al. Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. Transfusion 2001; 41: 184–189.

    Article  CAS  Google Scholar 

  12. Campbell LJ, Maher DW, Tay DL et al. Marrow proliferation and the appearance of giant neutrophils in response to recombinant human granulocyte colony stimulating factor (rhG-CSF). Br J Haematol 1992; 80: 298–304.

    Article  CAS  Google Scholar 

  13. Ulich TR, del Castillo J, Souza L . Kinetics and mechanisms of recombinant human granulocyte-colony stimulating factor-induced neutrophilia. Am J Pathol 1988; 133: 630–638.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Shimoni A, Nagler A, Kaplinsky C et al. Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysis. Leukemia 2002; 16: 1413–1418; discussion 1419–1422.

    Article  CAS  Google Scholar 

  15. Bielorai B, Golan H, Trakhtenbrot L et al. Combined analysis of morphology and FISH in follow-up of minimal residual disease (MRD) in a child with ph+ acute lymphoblastic leukemia. Cancer Genet Cytogenet 2002; 138: 64–68.

    Article  CAS  Google Scholar 

  16. Jakubowski A, Gabrilove J . Granulocyte colony stimulating factor (G-CSF): biology and clinical status. Cancer Biother Radiopharm 1996; 11: 5–20.

    Article  CAS  Google Scholar 

  17. Clarke DJ, Gimenez-Abian JF . Checkpoints controlling mitosis. Bioessays 2000; 22: 351–363.

    Article  CAS  Google Scholar 

  18. Schmidt-Mende J, Tehranchi R, Forsblom AM et al. Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts. Leukemia 2001; 15: 742–751.

    Article  CAS  Google Scholar 

  19. Villunger A, O'Reilly LA, Holler N et al. Fas ligand, Bcl-2, granulocyte colony-stimulating factor, and p38 mitogen-activated protein kinase: regulators of distinct cell death and survival pathways in granulocytes. J Exp Med 2000; 192: 647–658.

    Article  CAS  Google Scholar 

  20. Kaplinsky C, Lotem J, Sachs L . Protection of human myeloid leukemic cells against doxorubicin-induced apoptosis by granulocyte–macrophage colony-stimulating factor and interleukin 3. Leukemia 1996; 10: 460–465.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Hemato-Oncology, The Chaim Sheba Medical Center, Tel-Hashomer, Israel

    C Kaplinsky, L Trakhtenbrot, A Toren, N Amariglio, G Rechavi & S Izraeli

  2. Institute of Hematology, The Chaim Sheba Medical Center, Tel-Hashomer, Israel and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

    I Hardan

  3. BioView Ltd, Nes Ziona, Israel

    M Reichart & M Daniely

Authors
  1. C Kaplinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Trakhtenbrot
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I Hardan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Reichart
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Daniely
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Toren
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N Amariglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G Rechavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Izraeli
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaplinsky, C., Trakhtenbrot, L., Hardan, I. et al. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF. Bone Marrow Transplant 32, 31–34 (2003). https://doi.org/10.1038/sj.bmt.1703902

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703902

Keywords

This article is cited by

Search

Advanced search

Quick links